HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
Author Information
Author(s): Andersen Mads Hald, Soerensen Rikke B, Becker Jürgen C, thor Straten Per
Primary Institution: Center for Cancer Immunotherapy (CCIT), Department of Hematology, Herlev University Hospital
Hypothesis
Can HLA-A24 restricted peptides derived from survivin be used in immunotherapy for cancer?
Conclusion
The study identifies a promising HLA-A24-restricted epitope from survivin that could be targeted in cancer immunotherapy.
Supporting Evidence
- HLA-A24 is the most frequent HLA allele in Asia, making it a key target for survivin-based immunotherapy.
- Survivin is over-expressed in almost all cancers, indicating its potential as a vaccination candidate.
- Strong T-cell responses were detected against the survivin-derived peptide in multiple cancer patients.
Takeaway
Researchers found a part of a protein called survivin that can help the body's immune system fight cancer, especially in people with a specific genetic marker.
Methodology
Peripheral blood lymphocytes from HLA-A24 positive cancer patients were isolated and tested for responses to survivin-derived peptides using ELISPOT assays.
Limitations
The expression of the survivin-2B variant is low in many cancers, which may limit its effectiveness as a vaccine target.
Participant Demographics
HLA-A24 positive cancer patients from various origins.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website